Engflag

Amorolfina

Quick links to important sections

Amorolfina

Amorolfina_FR

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Amorolfina

Property Description
Active Ingredient Amorolfine hydrochloride
Form Primarily Nail lacquer (5% concentration), Topical solution, Cream
Pharmacological Class Antifungal agent (Morpholine derivative)
Common Use Treating superficial fungal infections of the nail and skin
Origin Synthetic compound

What Type of Medicine is Amorolfina?

Amorolfina is a synthetic medication containing the active substance Amorolfine hydrochloride, which is pharmacologically classified as a distinct topical antifungal agent. Its primary design is to act as an antimycotic, a drug used to eliminate or inhibit the growth of pathogenic fungi. The compound belongs to the morpholine derivative chemical class. This attribute is associated with the medicine's ability to combat a wide variety of fungal pathogens.

Composition, Origin, and Available Preparations

Amorolfina is a synthetic, single-ingredient compound formulated exclusively for topical use, ensuring targeted activity at the application site. The most prevalent presentation is typically as a medicated nail lacquer or a topical solution. This formulation, particularly the nail lacquer, is a key differentiating factor, enabling the high-concentration delivery of the active ingredient, Amorolfine, into hard tissues like the nail plate. This specialized system is designed to maximize localized action where it is most needed, such as in the treatment of fungal nail infections.

General Purpose and Mechanism Principle

The general purpose of Amorolfina is to resolve superficial fungal infections by fundamentally compromising the structural integrity of the fungal cell membrane. The active ingredient employs a dual mechanism that interferes with the fungus's ability to synthesize ergosterol, a crucial lipid required for the cell wall's health and function. This unique inhibition results in a dual therapeutic outcome: it is both fungistatic (arresting growth) and fungicidal (killing the fungal organism), thereby ensuring the elimination of the source of infection.

What side effects are possible with Amorolfina?

Possible Side Effects and Safety Information

Amorolfina's official safety profile is predominantly characterized by adverse reactions that are localized to the application site, reflecting its topical use. The systemic absorption of the active substance is officially documented as very low. Adverse reactions are classified according to frequency as documented in regulatory sources.

Localized effects such as a skin burning sensation at the application site are classified as Very Rare (affecting less than 1 in 10,000 users). Other reactions involving the nail and surrounding skin, including nail discolouration, brittle nails (onychorrhexis), and other nail disorders, are formally categorized as Rare (affecting between 1 in 10,000 and 1 in 1,000 users). Additionally, post-marketing experience has documented events such as contact dermatitis, erythema, and pruritus, though their frequency is classified as Not Known.

Adverse effects are formally grouped into Skin and subcutaneous tissue disorders and Immune system disorders. While rare, a serious systemic reaction, Hypersensitivity (Systemic Allergic Reaction), is noted in regulatory documents. This reaction may involve swelling of the face, lips, tongue, or throat, or a severe skin rash.

Specific Population Safety Constraints apply. The medicine is not recommended for use in children and adolescents (under 18 years) due to a lack of specific clinical safety data. Use is also not recommended during pregnancy and lactation unless clearly necessary, based on limited human experience. The only formal Contraindication is known hypersensitivity to Amorolfine or any of the excipients.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — official regulatory information for Amorolfina

Overdose scope

Category Official Regulatory Statement
Documented overdose presentations No systemic signs of overdose are expected following the intended topical application (nail lacquer or cream).
Physiological systems affected (as stated in label) (No specific physiological system effects are documented in the overdose section due to the low systemic exposure.)
Dose-related or exposure-related factors (if applicable) The single documented scenario requiring action is the accidental oral ingestion of the medicinal product.
Population-specific overdose notes (if applicable) (No population-specific considerations regarding overdose severity are explicitly stated in the official regulatory documentation.)
Emergency-response statements (as written in official documents) For accidental oral ingestion, patients must contact a doctor, pharmacist, or the nearest hospital straight away.
When immediate medical help is required (label-derived phrasing only) Urgent medical help must be sought if the patient experiences signs of a systemic allergic reaction (hypersensitivity), such as difficulty breathing or swelling of the face, lips, tongue, or throat.

Overdose classifications (high-level)

Category Official Regulatory Statement
Severity classification (as defined in official documents) Topical overdose is classified as having no expected systemic toxicity due to low systemic absorption.
Regulatory basis (EMA / FDA / etc.) Information is derived from the Summary of Product Characteristics (SmPC) and equivalent government regulatory labeling.
Overdose-context constraints (as defined in official documents) Management for accidental ingestion is restricted to taking appropriate symptomatic measures if needed.

Resulting overdose structure

Official overdose statements:

  • No systemic signs of overdose are expected from the intended topical application of the medicine.
  • The only circumstance requiring specific intervention is accidental oral ingestion, for which patients must contact a doctor, pharmacist, or the nearest hospital straight away.
  • In cases of accidental oral ingestion, management is limited to taking appropriate symptomatic measures.
  • Urgent medical help must be sought immediately if symptoms of a systemic allergic reaction (hypersensitivity) occur.

Connection to the overall overdose profile (2–4 sentences):

The regulatory documentation explicitly defines the overdose profile of Amorolfina based on the negligible systemic absorption associated with its topical use. This documentation indicates that no systemic overdose signs are anticipated, directing all regulatory attention to the specific procedural response required for accidental oral ingestion. Furthermore, official labeling mandates seeking immediate medical attention if the patient develops signs of a severe allergic reaction, classifying this acute hypersensitivity event as a critical trigger for emergency response.

Therapeutic Uses of Amorolfina

What Amorolfina Treats: Main Uses and Benefits

Amorolfina is relevant in areas where short-term symptom management is appropriate for certain fungal infections. This medication is commonly used to help manage the symptoms associated with fungal nail disease (onychomycosis) and various superficial skin mycoses, including athlete's foot (Tinea pedis) and ringworm.

Therapeutic Focus and Symptom Relief

The medication is primarily applied to address the symptoms that interfere with daily comfort and create noticeable physiological strain in affected areas. For the nails, it is used for managing the process of infection clearance and contributes to supporting a normalized nail appearance by easing issues like discoloration, thickening, and brittleness. In common clinical scenarios, it plays a role in managing fungal issues by serving as the sole treatment for localized infections or as a supportive measure in more extensive cases.

Furthermore, it may be used to support long-term management against recurrence, offering symptomatic relief that helps patients cope more steadily with symptom fluctuations.

Quick Fact: Relief for Fungal Discomfort
Amorolfina is relevant for easing symptoms related to inflammatory or irritative states caused by fungal activity, helping to manage localized itching, redness, and scaling associated with common skin mycoses.

Regulatory References

  1. Health Products Regulatory Authority (HPRA) Summary of Product Characteristics

Eligibility and Restrictions for Use

The eligibility profile for Amorolfina (Amorolfine 5% Nail Lacquer) is defined by official regulatory criteria that specify the approved patient population and conditions for exclusion.

The single absolute restriction is a contraindication for patients with known hypersensitivity to the active substance or any of the product's excipients.

Eligibility Status Affected Population Regulatory Basis
Allowed Adults and the Elderly Approved population; no specific dosage adjustment for older adults.
Not Recommended Children and Adolescents (under 18) Lack of clinical data/experience available to date.

The medicine is further categorized for use based on physiological status and underlying health. Regulatory documents state that Amorolfina should be avoided during both pregnancy and breastfeeding due to limited human data and unknown excretion into breast milk. Additionally, patients with certain comorbidities must seek prior medical advice, as their condition may require systemic therapy instead of topical application. These conditions include diabetes mellitus, peripheral vascular diseases, and immune system disorders. No explicit restrictions are documented for use in patients with renal or hepatic impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information regarding interactions with Amorolfine hydrochloride (Amorolfina) is heavily influenced by its specialized topical formulation. Due to the negligible systemic absorption of the active ingredient through the nail plate and skin, regulatory authorities commonly state that there are no known interactions with other medicines.

Interaction Scope and Regulatory Restrictions

Category Regulatory Documentation
Systemic Medicinal Products No known interactions are documented with other systemically administered medicines.
Mechanistic Basis No pharmacokinetic (e.g., CYP enzymes) or pharmacodynamic interaction mechanisms are documented.
Food, Alcohol, or Supplements No interactions with food, alcohol, or supplements are documented in official regulatory materials.

The regulatory profile focuses instead on mandatory local constraints regarding co-application on the nail plate:

  • Contraindicated Combinations: The use of artificial nails must be avoided during the entire treatment period.
  • Timing-Based Separation: If cosmetic nail varnish is applied, it must be removed before the next scheduled application of Amorolfina. The varnish should only be applied at least 10 minutes after the medicine has been applied.

These constraints ensure the active substance remains effective at the site of infection and maintains the intended level of contact with the nail.

Mechanism of Action

Mechanism of Action: Inhibition of Fungal Sterol Synthesis

Amorolfine acts specifically within the ergosterol biosynthesis pathway of the fungal cell membrane. Its mechanism involves non-competitive inhibition of two key enzymes: mathbfDelta14-reductase and mathbfDelta7-Delta8-isomerase.

This dual enzymatic block modifies early molecular steps, leading to a fundamental shift in sterol composition. The normal, essential sterol, ergosterol, is depleted, while dysfunctional sterol intermediates, such as ignosterol and other Delta8- and Delta14-sterols, accumulate in the cytoplasmic membrane. This mechanistic cascade severely compromises the structural integrity, fluidity, and permeability of the fungal membrane.

The resulting system-level physiological consequence is the impairment of critical membrane-associated processes. The structural compromise leads to the leakage of intracellular components and progressive functional decay in the fungal cell.

Dosage and Administration Information

Administration Guidelines for Amorolfina Nail Lacquer

Amorolfina (amorolfine) medicated nail lacquer is applied topically to the affected nail(s) and is used according to established procedural steps. The treatment is administered on a weekly schedule, and continuous adherence is required for the specified duration.

Procedural and Dosing Rules

Administration Scope Description
Route of Administration Topical, to the surface of the affected nail(s).
Dosing Frequency Apply once or twice a week.
Treatment Duration Continuous use is required for approximately six months for fingernails and nine to twelve months for toenails, until the infected nail is fully replaced by a healthy one.
Pre-Application Steps Before the first application and before each re-application, the nail must be filed down as thoroughly as possible using a supplied nail file, and the nail surface must be cleansed and degreased with a provided swab. The files used on affected nails should not be used on healthy nails.
Special Conditions Wear impermeable gloves when handling organic solvents (e.g., paint thinners) to protect the lacquer layer from being removed. If cosmetic nail varnish is applied, a minimum interval of 10 minutes must be respected after applying the medicated lacquer, and the cosmetic varnish must be removed before the next scheduled application.
Missed Dose If an application is missed, it should be applied as soon as possible, then treatment should continue on the originally scheduled day.

This defined procedure—including pre-treatment filing, weekly application, and long-term commitment—structures the use of the medicine, ensuring the active ingredient is applied correctly and remains on the nail for the entire therapeutic course required for nail regeneration.

Recent Clinical Evidence

Recent Clinical Evidence Overview

Clinical research has focused on amorolfina 5% nail lacquer for the topical management of onychomycosis (fungal nail infection). The consensus among regulatory bodies is that topical treatments, including amorolfina, are generally indicated for mild to moderate infections where the nail matrix is not heavily involved.

Mechanism of Research Interest

Research investigated amorolfina's actions, which involve disrupting fungal cell membrane integrity. Studies suggest this occurs by inhibiting two key enzymes involved in the synthesis of ergosterol, an essential component of the fungal membrane. This action leads to the accumulation of abnormal sterols within the fungal cell.

Efficacy Studies and Outcomes

Early clinical trials reported cure rates in the range of 38% to 46% for toenail onychomycosis, based on both negative fungal culture (mycological cure) and visual clearance (clinical cure), following six months of treatment. However, recent, well-controlled primary care trials exploring outcomes against placebo in patients with mild to moderately severe onychomycosis have reported mixed findings.

Study Type Treatment Setting Key Finding (Mycological Cure)
Comparative RCTs (Topical Monotherapy) Primary Care Some studies did not find a significant difference between amorolfina and placebo.
Combination Therapy Trial Severe Onychomycosis Combination with oral antifungals was associated with higher cure rates compared to oral monotherapy.

Overall, the evidence suggests that amorolfina may be a suitable option for early-stage infections but its application is highly dependent on the severity and extent of the nail condition. Its effectiveness in severe cases is mainly explored in combination with oral therapies.

Frequently Asked Questions (FAQ)

Common questions about Amorolfina (FAQ)

Q: Does Amorolfina only treat toenail and fingernail fungus, or can it be used for other skin conditions?

According to regulatory documents, the product is specifically indicated for the treatment of fungal infections of the nails (onychomycoses). These infections are typically caused by dermatophytes, yeasts, and molds. The nail lacquer formulation is designed for this targeted nail application, not for general treatment of other superficial skin conditions.

Q: Is there evidence about the effectiveness of Amorolfina for treating mold infections on nails?

The official product information notes that the active substance, amorolfine, is classified as a broad-spectrum topical antimycotic. Regulatory documents list a range of susceptible organisms that includes various molds, such as species like Alternaria, Hendersonula, Scopulariopsis, and Aspergillus, in addition to dermatophytes and yeasts.

Q: Why does the treatment duration for fingernails seem shorter than for toenails?

Regulatory documents state that the duration of treatment is required to be approximately six months for fingernails and nine to twelve months for toenails. This difference is consistent with the duration needed to achieve complete nail regeneration and cure, as indicated in the product's administration guidelines.

Q: How long do patients typically use the product before deciding if it is working?

Official regulatory information states that a review of the treatment is recommended at intervals of approximately three months. As the goal is the complete regrowth of a healthy nail, results are generally assessed over this longer, medically guided timeframe.

Q: What happens if the treatment is stopped too soon?

Regulatory documents emphasize that continuous treatment is required until the nail is completely regenerated and cured to meet the stated therapeutic goal. This long-term commitment is necessary to ensure the elimination of the infection.

Q: If I accidentally get Amorolfina on the skin around my nail, is that a safety concern?

Regulatory documents explicitly advise that the nail lacquer should not be applied to the skin around the nail. The formulation contains ethanol (alcohol), and a burning sensation on damaged skin is noted as a potential reaction in regulatory warnings.

Q: Can Amorolfina be applied to the skin if the infection has spread slightly off the nail?

Regulatory documents explicitly advise that the nail lacquer should not be applied to the skin around the nail. The product is specifically formulated and indicated for application on the hard nail plate itself.

Q: Are there any restrictions on activity, like swimming or showering, after application?

Once the nail lacquer is dry, official product information states that it is unaffected by water and soap, allowing for normal showering and washing of hands and feet. However, the administration guidelines state that impermeable gloves should be worn when handling organic solvents, such as paint thinners, as these can remove the lacquer.

Q: Does Amorolfina have any impact on the healthy part of the nail?

Adverse reactions related to the nail have been reported, though they are rare (affecting up to 1 in 1,000 people). These potential reactions may include nail disorders such as discolouration, broken nails, or brittle nails (onychorrhexis).

Q: What happens if a small amount of the lacquer is accidentally swallowed?

Due to the topical application, regulatory documents state that no systemic signs of overdose are expected following normal use. Official documentation states that in the event of accidental oral ingestion, appropriate symptomatic measures should be taken.

Q: What are the most common reported side effects mentioned in official drug documents?

The most commonly reported adverse drug reactions are rare, affecting up to 1 in 1,000 people. These potential reactions primarily involve the nail, and include nail disorders such as discolouration, broken nails, or brittle nails. Skin reactions like redness (erythema) or itching (pruritus) have also been reported, but their frequency is unknown.

Q: Are there any reported side effects related to the smell or fumes from the lacquer?

The product's patient information contains specific warnings, advising users not to inhale the lacquer and to avoid contact with the eyes, ears, and mucous membranes. This is due to the volatile components (excipients) in the formulation.

Q: Can Amorolfina be used at the same time as other topical skin medications?

According to official regulatory documents, no interaction studies have been performed regarding the concomitant use of the nail lacquer with other topical skin medications. The primary interactions listed relate to other nail products, such as avoiding artificial nails.

How should Amorolfina be stored and disposed of?

How to Store and Dispose of Amorolfine Nail Lacquer

Storage and disposal must strictly adhere to regulatory labeling, which addresses the product's stability and flammability.

Official Storage Requirements

  • Temperature and Fire Protection: The lacquer must be stored below 30°C and is required to be protected from heat and open flame due to its flammable components. It should be kept away from lit cigarettes or heat-generating devices like hair dryers.
  • Container Integrity: To maintain stability, the bottle must be kept tightly closed immediately after every use, and stored upright.
  • Child Safety: The medicine must be stored out of the sight and reach of children.
  • Stability: The product's shelf life after the first opening is defined as 6 months.

Disposal

Unused or expired Amorolfine nail lacquer and all waste materials, including the used flammable cleansing swabs, must be disposed of in accordance with local and national requirements. Medicines should not be thrown away via household waste or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Amorolfina found in:

A-Z Index: